Literature DB >> 31149241

THE CRUCIAL ROLE OF THE WNT SYSTEM IN BONE REMODELLING.

D Grigorie1, U H Lerner2.   

Abstract

The maintenance of bone mass is critically dependent on the balance between bone formation by osteoblasts and bone resorption by osteoclasts, processes in which osteocytes play also an important role. The activities of these bone cells are regulated by a variety of endocrine and paracrine factors of which sex steroids, parathyroid hormone, 1.25(OH)2-vitamin D3, glucocorticoids, retinoids and thyroid hormones are the most well known systemic factors. To the long list of locally acting factors belong cytokines and growth factors. This list was extended some 15 years ago by the discovery of the very important role of the WNT signalling system for the maintenance of bone mass. The first evidence of its role was the findings that mutations in the LRP5 gene, encoding a co-receptor in WNT-signaling, could result in either gain or loss of bone mass, i.e. either high bone mass or osteoporosis. This was a most unexpected observation since no indications existed prior to this discovery that the WNT signalling system had a role in bone remodeling. Since then, many observations have been made demonstrating the important role of different WNTs in regulating bone formation and resorption. Interestingly, some of these findings have demonstrated that trabecular and cortical bone are regulated by different mechanisms. It is the aim of the present overview to give the readers an insight into the WNT signalling system and its role in bone remodeling.

Entities:  

Keywords:  WNTs; bone; bone resorption; osteoclasts; sclerostin

Year:  2018        PMID: 31149241      PMCID: PMC6516605          DOI: 10.4183/aeb.2018.90

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  5 in total

1.  CHANGES OF WNT/B-CATENIN SIGNALING AND DIFFERENTIATION POTENTIAL OF BONE MARROW MESENCHYMAL STEM CELLS IN PROCESS OF BONE LOSS IN OVARIECTOMIZED RATS.

Authors:  W Ren; D Gan; G Tan; H Xue; N Li; Z Xu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

2.  Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.

Authors:  Jennifer R Diamond; Carlos Becerra; Donald Richards; Alain Mita; Cynthia Osborne; Joyce O'Shaughnessy; Chun Zhang; Randall Henner; Ann M Kapoun; Lu Xu; Bob Stagg; Shailaja Uttamsingh; Rainer K Brachmann; Azeez Farooki; Monica Mita
Journal:  Breast Cancer Res Treat       Date:  2020-08-14       Impact factor: 4.872

Review 3.  Focus on Osteosclerotic Progression in Primary Myelofibrosis.

Authors:  Mariarita Spampinato; Cesarina Giallongo; Alessandra Romano; Lucia Longhitano; Enrico La Spina; Roberto Avola; Grazia Scandura; Ilaria Dulcamare; Vincenzo Bramanti; Michelino Di Rosa; Nunzio Vicario; Rosalba Parenti; Giovanni Li Volti; Daniele Tibullo; Giuseppe A Palumbo
Journal:  Biomolecules       Date:  2021-01-19

4.  Biocompatibility pathways and mechanisms for bioactive materials: The bioactivity zone.

Authors:  David F Williams
Journal:  Bioact Mater       Date:  2021-08-26

5.  Cumulative Effects of Strontium Ranelate and Impact Exercise on Bone Mass in Ovariectomized Rats.

Authors:  Priscilla Aveline; Annabelle Cesaro; Marija Mazor; Thomas M Best; Eric Lespessailles; Hechmi Toumi
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.